Aarey Drugs & Pharmaceuticals shareholding pattern

AAREYDRUGS

64.29

6.86 (-9.64%)
Last updated on 1 Feb, 2026 | 15:59 IST
alert_iconwatchlist_icon
BUYSELL

alert_iconThe current prices are delayed, login to your account for live prices

Aarey Drugs & Pharmaceuticals Shareholding Pattern

  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

39.06%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

3.86%

Domestic Institutional Investors

0%

Retail

57.09%

Others

-0.01%

Total Promoters
MAR '25
44.8%
JUN '25
44.8%
SEP '25
44.8%
DEC '25
39.06%

Summary

For Year 2025-26, Aarey Drugs & Pharmaceuticals reports the following shareholding: Total Promoters at 39.06%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 3.86%, Domestic Institutional Investors at 0%, and Retail at 57.09%. This breakdown provides a quick snapshot of ownership distribution for Aarey Drugs & Pharmaceuticals in 2025-26.

Aarey Drugs & Pharmaceuticals FAQs

As of 02-2026, the promoter shareholding in Aarey Drugs & Pharmaceuticals stands at 39.06% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Aarey Drugs & Pharmaceuticals is 3.86% and 0% respectively.

The retail shareholding of the Aarey Drugs & Pharmaceuticals is 57.09%.

Changes in shareholding patterns of Aarey Drugs & Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Aarey Drugs & Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.